+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Retinal Vein Occlusion - Pipeline Review, H2 2019

  • ID: 4901306
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 107 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 3SBio Inc
  • Cell Medica Ltd
  • Graybug Vision Inc
  • Lupin Ltd
  • Novartis AG
  • Outlook Therapeutics Inc
  • MORE
Retinal Vein Occlusion - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Retinal Vein Occlusion - Pipeline Review, H2 2019, provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape.

Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol and age.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Retinal Vein Occlusion - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 6, 2, 4 and 1 respectively.

Retinal Vein Occlusion (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinal Vein Occlusion (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinal Vein Occlusion (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinal Vein Occlusion (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinal Vein Occlusion (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 3SBio Inc
  • Cell Medica Ltd
  • Graybug Vision Inc
  • Lupin Ltd
  • Novartis AG
  • Outlook Therapeutics Inc
  • MORE
Introduction
Report Coverage
Retinal Vein Occlusion - Overview
Retinal Vein Occlusion - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Retinal Vein Occlusion - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Retinal Vein Occlusion - Companies Involved in Therapeutics Development
3SBio Inc
Addmedica SAS
Aerpio Pharmaceuticals Inc
Annexin Pharmaceuticals AB
Calpain Therapeutics Pty Ltd
Cell Medica Ltd
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Eyevensys SAS
Gene Signal International SA
Graybug Vision Inc
Kodiak Sciences Inc
Lupin Ltd
NeuBase Therapeutics Inc
Novartis AG
Ocular Therapeutix Inc
Outlook Therapeutics Inc
Oxurion NV
Panoptes Pharma GesmbH
Retinal Vein Occlusion - Drug Profiles
Retinal Vein Occlusion - Dormant Projects
Retinal Vein Occlusion - Discontinued Products
Retinal Vein Occlusion - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Retinal Vein Occlusion, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Retinal Vein Occlusion - Pipeline by 3SBio Inc, H2 2019
Retinal Vein Occlusion - Pipeline by Addmedica SAS, H2 2019
Retinal Vein Occlusion - Pipeline by Aerpio Pharmaceuticals Inc, H2 2019
Retinal Vein Occlusion - Pipeline by Annexin Pharmaceuticals AB, H2 2019
Retinal Vein Occlusion - Pipeline by Calpain Therapeutics Pty Ltd, H2 2019
Retinal Vein Occlusion - Pipeline by Cell Medica Ltd, H2 2019
Retinal Vein Occlusion - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2019
Retinal Vein Occlusion - Pipeline by Eyevensys SAS, H2 2019
Retinal Vein Occlusion - Pipeline by Gene Signal International SA, H2 2019
Retinal Vein Occlusion - Pipeline by Graybug Vision Inc, H2 2019
Retinal Vein Occlusion - Pipeline by Kodiak Sciences Inc, H2 2019
Retinal Vein Occlusion - Pipeline by Lupin Ltd, H2 2019
Retinal Vein Occlusion - Pipeline by NeuBase Therapeutics Inc, H2 2019
Retinal Vein Occlusion - Pipeline by Novartis AG, H2 2019
Retinal Vein Occlusion - Pipeline by Ocular Therapeutix Inc, H2 2019
Retinal Vein Occlusion - Pipeline by Outlook Therapeutics Inc, H2 2019
Retinal Vein Occlusion - Pipeline by Oxurion NV, H2 2019
Retinal Vein Occlusion - Pipeline by Panoptes Pharma GesmbH, H2 2019
Retinal Vein Occlusion - Dormant Projects, H2 2019
Retinal Vein Occlusion - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Retinal Vein Occlusion, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 3SBio Inc
  • Addmedica SAS
  • Aerpio Pharmaceuticals Inc
  • Annexin Pharmaceuticals AB
  • Calpain Therapeutics Pty Ltd
  • Cell Medica Ltd
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd
  • Eyevensys SAS
  • Gene Signal International SA
  • Graybug Vision Inc
  • Kodiak Sciences Inc
  • Lupin Ltd
  • NeuBase Therapeutics Inc
  • Novartis AG
  • Ocular Therapeutix Inc
  • Outlook Therapeutics Inc
  • Oxurion NV
  • Panoptes Pharma GesmbH
Note: Product cover images may vary from those shown
Adroll
adroll